vs

Side-by-side financial comparison of Essent Group Ltd. (ESNT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $37.2M, roughly 8.4× Organogenesis Holdings Inc.). On growth, Essent Group Ltd. posted the faster year-over-year revenue change (-0.8% vs -57.1%). Over the past eight quarters, Essent Group Ltd.'s revenue compounded faster (2.3% CAGR vs -46.5%).

Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ESNT vs ORGO — Head-to-Head

Bigger by revenue
ESNT
ESNT
8.4× larger
ESNT
$312.4M
$37.2M
ORGO
Growing faster (revenue YoY)
ESNT
ESNT
+56.2% gap
ESNT
-0.8%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ESNT
ESNT
Annualised
ESNT
2.3%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESNT
ESNT
ORGO
ORGO
Revenue
$312.4M
$37.2M
Net Profit
$155.0M
Gross Margin
30.8%
Operating Margin
59.1%
-185.1%
Net Margin
49.6%
Revenue YoY
-0.8%
-57.1%
Net Profit YoY
-7.7%
EPS (diluted)
$1.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESNT
ESNT
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$312.4M
$225.6M
Q3 25
$311.8M
$150.9M
Q2 25
$319.1M
$101.0M
Q1 25
$317.6M
$86.7M
Q4 24
$315.0M
$126.7M
Q3 24
$316.6M
$115.2M
Q2 24
$312.9M
$130.2M
Net Profit
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
$155.0M
$43.7M
Q3 25
$164.2M
$21.6M
Q2 25
$195.3M
$-9.4M
Q1 25
$175.4M
$-18.8M
Q4 24
$167.9M
$7.7M
Q3 24
$176.2M
$12.3M
Q2 24
$203.6M
$-17.0M
Gross Margin
ESNT
ESNT
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ESNT
ESNT
ORGO
ORGO
Q1 26
-185.1%
Q4 25
59.1%
28.1%
Q3 25
63.9%
13.7%
Q2 25
72.4%
-12.5%
Q1 25
65.2%
-30.9%
Q4 24
61.9%
8.1%
Q3 24
65.6%
5.4%
Q2 24
76.4%
-10.7%
Net Margin
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
49.6%
19.4%
Q3 25
52.7%
14.3%
Q2 25
61.2%
-9.3%
Q1 25
55.2%
-21.7%
Q4 24
53.3%
6.1%
Q3 24
55.6%
10.7%
Q2 24
65.1%
-13.1%
EPS (diluted)
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
$1.61
$0.31
Q3 25
$1.67
$0.11
Q2 25
$1.93
$-0.10
Q1 25
$1.69
$-0.17
Q4 24
$1.59
$0.05
Q3 24
$1.65
$0.09
Q2 24
$1.91
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESNT
ESNT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.8B
Total Assets
$7.4B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESNT
ESNT
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
$5.8B
$300.1M
Q3 25
$5.7B
$255.1M
Q2 25
$5.7B
$233.2M
Q1 25
$5.7B
$242.9M
Q4 24
$5.6B
$262.9M
Q3 24
$5.6B
$278.5M
Q2 24
$5.4B
$263.5M
Total Assets
ESNT
ESNT
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$7.4B
$598.7M
Q3 25
$7.4B
$509.8M
Q2 25
$7.2B
$461.1M
Q1 25
$7.2B
$467.4M
Q4 24
$7.1B
$497.9M
Q3 24
$7.1B
$446.3M
Q2 24
$6.7B
$443.2M
Debt / Equity
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESNT
ESNT
ORGO
ORGO
Operating Cash FlowLast quarter
$856.1M
Free Cash FlowOCF − Capex
$848.7M
FCF MarginFCF / Revenue
271.7%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
5.52×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
$856.1M
$39.4M
Q3 25
$215.9M
$3.1M
Q2 25
$189.5M
$-32.9M
Q1 25
$221.6M
$-19.9M
Q4 24
$861.5M
$10.9M
Q3 24
$229.2M
$8.7M
Q2 24
$188.7M
$4.7M
Free Cash Flow
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
$848.7M
$34.8M
Q3 25
$210.6M
$844.0K
Q2 25
$188.8M
$-36.5M
Q1 25
$221.3M
$-23.6M
Q4 24
$854.8M
$7.6M
Q3 24
$228.7M
$6.1M
Q2 24
$187.6M
$2.9M
FCF Margin
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
271.7%
15.4%
Q3 25
67.5%
0.6%
Q2 25
59.2%
-36.1%
Q1 25
69.7%
-27.2%
Q4 24
271.3%
6.0%
Q3 24
72.2%
5.3%
Q2 24
60.0%
2.2%
Capex Intensity
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
2.4%
2.1%
Q3 25
1.7%
1.5%
Q2 25
0.2%
3.6%
Q1 25
0.1%
4.2%
Q4 24
2.1%
2.7%
Q3 24
0.2%
2.2%
Q2 24
0.3%
1.4%
Cash Conversion
ESNT
ESNT
ORGO
ORGO
Q1 26
Q4 25
5.52×
0.90×
Q3 25
1.31×
0.14×
Q2 25
0.97×
Q1 25
1.26×
Q4 24
5.13×
1.43×
Q3 24
1.30×
0.71×
Q2 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESNT
ESNT

Mortgage Insurance Segment$192.4M62%
Other$120.0M38%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons